

Boyds International Life Sciences Group Limited

Unaudited Filleted Financial Statements

for the Year Ended 31 March 2025

Boys International Life Sciences Group Limited

Contents

Company Information	1
Balance Sheet	2
Notes to the Unaudited Financial Statements	3 to 6

Boyd's International Life Sciences Group Limited

Company Information

Directors	Mrs J M Boyd
	Mr N Chakrabarti
	Prof Alan Keith Boyd
Registered office	Electra House
	Crewe Business Park
	Crewe
	Cheshire
	CW1 6GL
Accountants	Bright Partnership Limited
	Suite 1 Armcon Business Park
	London Road South
	Poynton
	Cheshire
	SK12 1LQ

Boyd's International Life Sciences Group Limited

(Registration number: 13521126) Balance Sheet as at 31 March 2025

	Note	2025 £	2024 £
Fixed assets			
Investments in subsidiaries	4	86,737	38,995
Current assets			
Cash at bank and in hand		7,505	9,558
Creditors: Amounts falling due within one year		<u>(340)</u>	<u>(340)</u>
Net current assets		<u>7,165</u>	<u>9,218</u>
Net assets		<u>93,902</u>	<u>48,213</u>
Capital and reserves			
Share capital	5	4	4
Share-based payment reserve		86,717	38,975
Retained earnings		<u>7,181</u>	<u>9,234</u>
Shareholders' funds		<u>93,902</u>	<u>48,213</u>

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 21 October 2025 and signed on its behalf by:

.....

Mr N Chakrabarti
Director

The notes on pages [3](#) to [6](#) form an integral part of these financial statements.
Page 2

Boyds International Life Sciences Group Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

1 General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:

Electra House
Crewe Business Park
Crewe
Cheshire
CW1 6GL

These financial statements were authorised for issue by the Board on 21 October 2025.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

These financial statements are presented in sterling, which is the functional currency of the entity.

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Going concern

The financial statements have been prepared on a going concern basis. The Company meets its day-to-day working capital requirements through its cash reserves. The current economic conditions continue to create uncertainty, the Company's forecast and projections, taking into account of reasonable possible changes in trading performance, show that the Company ability to operate within the level of its cash reserves for a period of at least 12 months from the date of approval these statements.

Investments

Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company's shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Share based payments

The Boyds Group 'Boyd's International Life Sciences Group Limited' or 'the Parent' operates long term group incentive plans in which the Group grants equity-settled awards to employees of its subsidiaries. These awards are accounted for as equity-settled share-based payment transactions. The grant date fair value of share-based payments awards granted to employees is recognised as an employee expense in the Profit and Loss over the periods that the employee becomes unconditionally entitled to the awards, with a corresponding increase in equity.

The fair value of the options granted is measured at grant date. At each reporting date, an assessment is performed over the number of instruments expected to vest, taking into account the terms and conditions upon which the awards are granted. The amount recognised as an expense is adjusted to reflect the actual number of awards for which the related vesting conditions are expected to be met, such that amount ultimately recognised as an expense is based on the number of awards that meet the related vesting conditions at the vesting date.

Boyd's International Life Sciences Group Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

3 Staff numbers

The average number of persons employed by the company (including directors) during the year, was 3 (2024 - 3).

4 Investments

	2025	2024
	£	£
Investments in subsidiaries	20	20
Equity contribution	86,717	38,975
	<u>86,737</u>	<u>38,995</u>

Boyd's International Life Sciences Group Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 March 2025

Share-based payment transactions

The following awards “share options” were granted under the group long-term incentive plans. The Company recognised a total equity contribution of £86,717 (2024: £38,975). The terms and conditions of the grants are as follows:

a) Share incentive plan “SIP”
The Boyds Group granted 26,422 share options to Company employees during the year, subject to a service condition of three years from the award date. During the year, 7,016 share options were forfeited. At year-end, the total number of share options outstanding was 80,879.

The weighted-average fair value of share options granted at the grant date was £1.43 per option. The fair value was determined based on the Group’s return on capital employed, incorporating inputs and assumptions such as comparable company multiples, the average expected life of awards, and expected dividends. Service conditions are not considered in the measurement of the grant-date fair value of the services received.

b) Enterprise Management Incentives “EMIs”
The Boyds Group granted 22,000 share options to Company employees during the year, subject to a service condition of three years from the award date. During the year, 2,500 share options were forfeited. At year-end, the total number of share options outstanding was 49,500.

The weighted-average fair value of share options granted at the grant date was £1.28 per option. The fair value was determined based on the Group’s return on capital employed, incorporating inputs and assumptions such as comparable company multiples, the average expected life of awards, and expected dividends. Service conditions are not considered in the measurement of the grant-date fair value of the services received.

5 Share capital

Allotted, called up and fully paid shares

	2025		2024	
	No.	£	No.	£
Ordinary of £0.00 each issued	1,000,000	4	1,000,000	4
Ordinary A of £0.00 each issued	89,536	-	61,473	-
	1,089,536	4	1,061,473	4
Page 6				